Original Title: Transcatheter Aortic Valve Implantation for Paradoxical Low-Flow Low-Gradient Aortic Stenosis Patients. Reference: Nicolas Debry et al. Catheter Cardiovasc Interv. 2016 Mar;87(4):797-804. Courtesy of Dr. Carlos Fava. Approximately 10 to 13% of low-flow low-gradient severe aortic stenosis cases (LF-LG) have preserved left ventricular function. Its physiopathology remains unclear and it has been associated with a...
Original Title: Transcatheter Aortic Valve Replacement versus Surgical Valve Replacement in Intermediate-Risk Patients: A Propensity Score Analysis. Reference: Vinod H Thourani et al. Lancet Published Online April 3, 2016. Courtesy of Dr. Carlos Fava. The transcatheter Aortic Valve Replacement (TAVI) has shown benefits in high risk patients or inoperable patients, but there is little evidence...
This work represents the UK experience with the second generation repositionable and retrievable valve Lotus (Boston Scientific, Natick, Massachusetts). It prospectively included 228 patients of mean age 81.4 ± 7.6 and a logistic EuroScore of 17.5 ± 12.4. From the total number of patients, 187 (82%) received the valve for aortic stenosis, 7...
Original Title: 1-Year Outcomes with the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients with Severe Aortic Stenosis Results of the REPRISE II Study. Reference: Ian T. Meredith et al. J Am Coll Cardiol Intv. 2016;9(4):376-384. This analysis represents the first report at one year of 120 patients enrolled...
Original Title: Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation. 5 – Years Results of EVEREST II. Reference: Ted Feldman et al. J Am Coll Cardiol 2015;66:2844-54 Courtesy of Dr. Carlos Fava The MitraClip at 12 months in the EVEREST II trial showed similar outcomes to that of surgery, with improved ventricular remodeling and...
The new generation SAPIEN 3 valve was designed to reduce paravalvular aortic regurgitation. The objective of this work was to evaluate the influence of “oversizing” for SAPIEN 3 valve both in relation to the area and the perimeter and determine if calcium ring influences the degree of failure. A lesser degree of oversizing need it...
This study evaluated the safety and efficacy of the new repositionable self-expanding valve. The primary end point was all-cause mortality and stroke at 30 days. 60 patients were included and the possibility for reposition was used 22 times between 12 recaptures and 10 re-sheathed of the valve. All maneuvers were carried out successfully. A 30...
The aim of this study was to compare the results of transcatheter aortic valve replacement (TAVR) versus surgery in unselected patients with severe degenerative aortic stenosis. Patients were randomized 1:1 to TAVR (n = 145) or surgical replacement (n = 135). Those of TAVR group received Medtronic CoreValve self-expanding valve. The femoral access was used...
This study included 699 patients with severe aortic stenosis and high surgical risk of whom 348 received transcatheter aortic valve replacement (TAVR) and 351 received surgery. Previous reports of the results to one, two and three years and this work published simultaneously in Lancet reports the final follow-up at 5 years. The mortality at follow-up...
Multicenter prospective study included 2688 patients with a mean age of 81.4 years and 20.5 EuroScore. The all-cause mortality at 2 years was 27.7% (31.5% SOURCE study). The incidence of stroke at 2 years was 7.7% and moderate to severe aortic regurgitation 7.3% and 0.2% respectively. There was a significant improvement in functional class and...